Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours
ORION CORP NEW UNSP/ADR (ORINY)
NASDAQ:AMEX Investor Relations:
orion.fi/en/orion-group/investors/investor-relations
Company Research
Source: GlobeNewswire
ORION CORPORATION PRESS RELEASE 23 APRIL 2026 at 09.00 EEST Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours Orion Corporation (Orion Pharma) today announced the initiation of a Phase 1b/2 basket trial evaluating ODM-212, a potential best-in-class, oral pan-TEAD inhibitor, in combination with standard of care treatments in advanced mesothelioma, KRAS G12C mutated non-small cell lung cancer (NSCLC) and pancreatic cancer. The TEADCO trial is a multi-centre, open-label basket trial designed to evaluate the efficacy, safety, dose and tolerability of ODM-212 in combination with standard of care in these indications. The first cohort of the TEADCO trial evaluates ODM-212 in combination with ipilimumab and nivolumab as a first-line treatment for patients with advanced malignant pleural mesothelioma. ODM-212 has the potential to both exert direct anti-tumour act
Show less
Read more
Impact Snapshot
Event Time:
ORINY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORINY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORINY alerts
High impacting ORION CORP NEW UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ORINY
News
- Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDAGlobeNewswire
- Does Orion Oyj (HLSE:ORNBV) Dividend Hike Clarify Its Oncology-Pivot Capital Allocation Strategy? [Yahoo! Finance]Yahoo! Finance
- Orion Oyj (ORINY) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Developments [Yahoo! Finance]Yahoo! Finance
- The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company's key persons [Yahoo! Finance]Yahoo! Finance
- Notice to the Annual General Meeting of Orion Corporation [Yahoo! Finance]Yahoo! Finance